<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364908</url>
  </required_header>
  <id_info>
    <org_study_id>2013_65</org_study_id>
    <secondary_id>2014-A00735-42</secondary_id>
    <nct_id>NCT02364908</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus</brief_title>
  <acronym>ESSTIM</acronym>
  <official_title>Prospective Evaluation of Adherence to Antimalarials in Patients With Systemic Lupus and Role of Therapeutic Education</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Région Nord-Pas de Calais, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a biomedical, open label, therapeutic strategy, interventional, non-randomized,
      multicenter study to evaluate the non compliance to antimalarials in patients with systemic
      lupus in the Nord Pas-de-Calais region (FRANCE). It is conducted in two visits. These visits
      consist in obtaining blood sample, performing a clinical examination and filling in a
      questionnaire (Quality Of Life, Coping...).

      The goal for the noncompliants patients is to guide them towards the therapeutic education
      with professionals (nurses and physicians).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure of the frequency of patients with systemic lupus noncompliants to their antimalarials treatment.</measure>
    <time_frame>baseline, at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hydroxychloroquinémie</measure>
    <time_frame>between 6 months at 12 months</time_frame>
    <description>Monitoring of blood levels of hydroxychloroquinémie</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of non- adherent patients</measure>
    <time_frame>at 12 months</time_frame>
    <description>Identification of the number of non- adherent patients are being enrolled in Education Protocol Patient and number of sessions followed ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life scale Coping</measure>
    <time_frame>baseline, at 12 months</time_frame>
    <description>scale Coping ( WCC-R Par COUSSON et al. (1996) ) scale MASRI, scale MMAS-8-item</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Patients with Systemic Lupus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>therapeutic education</intervention_name>
    <description>This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.</description>
    <arm_group_label>Patients with Systemic Lupus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a systemic lupus with ACR criteria (at least 4 criterias)

          -  patients with antimalarials for at least 3 months with a minimum dose of 200 mg/day.

        Exclusion Criteria:

          -  patients who refuse to sign the informed consent

          -  patients who are under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hachulla, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Hôpital Duchenne</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Douai</name>
      <address>
        <city>Douai</city>
        <zip>59507</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Dr Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victor Provo Hospital</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valenciennes hospital</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>antimalarials</keyword>
  <keyword>therapeutic education</keyword>
  <keyword>Coping questionnaire</keyword>
  <keyword>MASRI questionnaire</keyword>
  <keyword>morisky medication adherence scale</keyword>
  <keyword>lupus Quality Of Life</keyword>
  <keyword>internal medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

